Marker Therapeutics is a clinical-stage immuno-oncology company engaging in the development and commercialization of T cell-based immunotherapies and peptide-based vaccines. Co. is developing three product candidates, including: autologous treatment of lymphoma, and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML); and off-the-shelf products in various indications. Co.'s clinical development programs are: MT-401, which is for the treatment of post-transplant AML; MT-401-OTS, which is for the treatment of AML; MT-601, which is for the treatment of pancreatic cancer; and MT-601, which is for the treatment of lymphoma. The MRKR stock yearly return is shown above.
The yearly return on the MRKR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MRKR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|